The MYC oncogenic pathway is activated in ~50–55% of breast cancers (BCs) with ~62% of TNBCs showing MYC oncogene amplification [8], suggesting that MYC represents an attractive, although difficult therapeutic target for TNBC. This evidence concerns the gene MYC and breast cancer.